Engaging HRSA-Supported Health Centers
The Biden-Harris Administration is committed to ensuring our nation's underserved communities and those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 treatments, such as oral antiviral treatments.
HRSA, in partnership with HHS partners, launched a program to directly allocate a limited supply of several oral antiviral treatments for the outpatient treatment of mild to moderate COVID-19 to select HRSA-supported health centers. The federal government secured a supply of these medications for distribution to the U.S. population following the issuance of Emergency Use Authorizations from the FDA.
This program supplements state/jurisdictional allocations and aims to ensure equitable access by providing an additional supply directly to HRSA-supported health centers.
Health Center Selections
The program began incrementally at approximately 200 select health centers that have pharmacy capacity and specialize in caring for particularly underserved and disproportionately affected populations (e.g., serve a significant number of people experiencing homelessness, migratory/seasonal agricultural workers, residents of public housing, people 65 or older, and those with limited English proficiency), or which have reported significant COVID-19 testing activity in the biweekly Health Center COVID-19 Survey.
On Monday, March 28, the program expanded to all health centers with pharmacy capacity, in support of the Biden-Harris Administration’s Test to Treat Initiative.
Technical Assistance Resources